Evotec SE (NASDAQ:EVO) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Christian Ehmann - Warburg Research Benjamin Jackson - Jefferies Joseph H ...

| --- | --- | --- | |-------------------------------------------------------------------------------|-----------------------|------------------------| | | | | | | | | | Nine-month results & update on transformation process Capital Market Briefing | | | | | Scientific Excellence | Operational Excellence | Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per year Previous internal combustion engine (ICE) vehicle plant transformed to facilitate EV production and accelerate delivery of Kia's strategic sustainable manufacturing and mobility goals Cutting-edge manufacturing initiatives include water-base ...

Evotec SE (NASDAQ:EVO) Q2 2024 Earnings Conference Call August 14, 2024 8:00 AM ET Company Participants Volker Braun - Executive Vice President, Head of Global Investor Relations and ESG Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Matthias Evers - Chief Business Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Benjamin Jackson - Jefferies Michael Ryskin - Bank of America ...

Evotec (EVO) achieved substantial progress in its strategic partnership with Bristol Myers Squibb (BMY) relating to building a molecular glue-based pipeline. This triggered a performance-based and program-based payment of $75 million payable to the company. Shares rose nearly 12% on Aug 13, likely in response to this announcement. The partnership was initially entered between Evotec and Celgene (acquired by Bristol Myers in 2019) in 2018 to discover and develop drugs in the field of molecular glue degraders ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Evotec SE (NASDAQ:EVO) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Volker Braun - EVP Head of Global IR and ESG Mario Polywka - Interim CEO Laetitia Rouxel - CFO Matthias Evers - Chief Business Officer Craig Johnston - COO Cord Dohrmann - Chief Scientific Officer Charles Weston - RBC Capital Markets Thibault Boutherin - Morgan Stanley Michael Ryskin - Bank of America Peter Verdult - Citigroup Inc. Ben Jackson - Jefferies Falko Friedrichs - Deutsche Bank Joseph Hedden - Rx Securities Christian E ...

| --- | --- | --- | |---------------------------------------------|-------|-------------------------------| | | | | | | | | | | | | | Resetting for profitable growth | | | | | | SCIENTIFIC ES ONAL EXCELLENCE | | Evotec SE, Q1 2024 Analyst Call, 2024-05-22 | | | PAGE 2 #RESEARCHNEVERSTOPS This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company ...

Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Volker Braun - Head of Global Investor Relations and ESG Iris Löw-Friedrich - Chairperson of the Supervisory Board Laetitia Rouxel - Chief Financial Officer Matthias Evers - Chief Business Officer Craig Johnston - Chief Operating Officer Conference Call Participants Peter Verdult - Citigroup Inc. Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Jacqueline Kisa - TD Cowen Falko Friedric ...

Revenues with partners in % Total Margin • Just – Evotec Biologics +111% PAGE 14 1 Differences may occur due to rounding Market dynamics and Q4 2023 performance triggered business review PAGE 15 PAGE 16 1. 2023 Performance review 2. Priority reset, Guidance & Outlook 3. Questions & Answers For 2024, we expect to continue operating in a challenging market Summary of current "buyer's market" dynamics PoC: Proof of Concept; IPO: Initial Public Offering; VC: Venture Capital; I&I: Inflammation and Immunology Sou ...